Phase II trial of nivolumab monotherapy and biomarker screening in patients with chemo-refractory germ cell tumors.

ABSTRACT:

Objectives

Germ cell tumors are highly susceptible to chemotherapy; however, there is a lack of established treatments for consistently relapsing germ cell tumor. Therefore, in this phase II study, we evaluated the efficacy and safety of nivolumab for relapsed germ cell tumor.

Methods

Seventeen adult patients (median age 34 years) with refractory primary germ cell tumor after second-line or higher chemotherapy were enrolled. Nivolumab was administered over 30 min at 240 mg/body every 2 weeks until disease progression or intolerable adverse event occurrence. The primary endpoint was the overall response rate.

Result

We performed a biomarker analysis of programmed death ligand-1 expression and genomic sequencing. Tumor histology revealed nonseminoma and seminoma in 14 a

SUBMITTER: Kawahara T 

PROVIDER: S-EPMC9545636 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature